Background: Studies using standardized cognitive assessments across disparate populations are often confounded by sociocultural differences, leading to a lack of comparative standards to assess the degree of Mild cognitive impairment (MCI). Thus, testing in diverse populations is essential in validating biomarkers for MCI and avoiding race and cultural confounders. Applying an identical, cross-culturally accepted, non-invasive, electrophysiological protocol, we test the hypothesis that the frontal neuromarkers for MCI are consistent in two samples of older adults in the US and China. Method: Using an identical, clinically friendly protocol with a wireless 14-channel headset (eMotiv), we recorded EEG signals along with accuracy and reaction times during a visual object working memory task in two samples of older adults. The Kentucky sample includes 12 Normal Cognition NC; (Mean age 68); 7 MCI (age 81) while the Beijing sample includes 11 NC (age 64) and 16 MCI (age 65). Each participant also received assessments in NACC UDS 3.0. The 10-min task asked each subject to remember two visual objects and then determine whether the subsequent object is a Match or Nonmatch to one of the two held in working memory. Result: We found that left frontal sites showed significant mean amplitude differences between MCI and NC during target match retrievals. The persons with MCI showed reduced responses to memory targets at the F3 and F7 sites in Kentucky. The MCIs’ reduction patterns were significant in the left frontal F3 but not significant at F7 in Beijing sample. The Beijing participants were on average younger than KY participants, leading to a reduction in quantitative signal change, however, the effect remains robust and parallels those from Kentucky. The current results using a fast and two-target memory task are consistent with previously reported results using 64-channels and a longer version of the memory task with single-target. Conclusion: We have validated frontal neuromarkers for MCI risk in two diverse samples. The current finding has significant implications for clinical practice which creates a path for the next step: large-scale, low-cost, and culturally-accepted screening for risk of cognitive decline in individuals, irrespective of their socio-cultural, geographical, or societal background.
Bibliographical notePublisher Copyright:
© 2022 the Alzheimer's Association.
ASJC Scopus subject areas
- Health Policy
- Developmental Neuroscience
- Clinical Neurology
- Geriatrics and Gerontology
- Cellular and Molecular Neuroscience
- Psychiatry and Mental health